Publicacións nas que colabora con Enrique Álvarez (12)

2017

  1. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: Results of a randomized, double-blind clinical trial

    BMC Psychiatry, Vol. 17, Núm. 1

2015

  1. Clinical and economic outcomes of adjunctive therapy with pregabalin or usual care in generalized anxiety disorder patients with partial response to selective serotonin reuptake inhibitors

    Annals of General Psychiatry, Vol. 14, Núm. 1

  2. Modeling the longitudinal latent effect of pregabalin on self-reported changes in sleep disturbances in outpatients with generalized anxiety disorder managed in routine clinical practice

    Drug Design, Development and Therapy, Vol. 9, pp. 4329-4340

  3. Pregabalin for the treatment of patients with generalized anxiety disorder with inadequate treatment response to antidepressants and severe depressive symptoms

    International Clinical Psychopharmacology, Vol. 30, Núm. 5, pp. 265-271

2013

  1. A comparative cost-analysis of initiating pregabalin or SSRI/SNRI therapy in benzodiazepine-resistant patients with generalized anxiety disorder in Spain

    Actas Espanolas de Psiquiatria, Vol. 41, Núm. 3, pp. 164-174

  2. Modelling the cost-effectiveness of pregabalin versus usual care in daily practice in the treatment of refractory generalised anxiety disorder in Spain

    Social Psychiatry and Psychiatric Epidemiology, Vol. 48, Núm. 6, pp. 985-996

2012

  1. Broadening of generalized anxiety disorders definition does not affect the response to psychiatric care: Findings from the observational ADAN study

    Clinical Practice and Epidemiology in Mental Health, Vol. 8, pp. 158-168

  2. Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder: A post hoc cost-effectiveness analysis in usual medical practice in Spain

    ClinicoEconomics and Outcomes Research, Vol. 4, Núm. 1, pp. 157-168

2007

  1. Effect of olanzapine or risperidone treatment on some cognitive functions in a one-year follow-up of schizophrenia outpatients with prominent negative symptoms

    European Neuropsychopharmacology, Vol. 17, Núm. 11, pp. 725-734

  2. Safety and tolerability of olanzapine versus risperidone: A one-year randomized study in outpatients with schizophrenia with prominent negative symptoms

    Actas Espanolas de Psiquiatria, Vol. 35, Núm. 2, pp. 105-114

2006

  1. A randomized, 1-year follow-up study of olanzapine and risperidone in the treatment of negative symptoms in outpatients with schizophrenia

    Journal of Clinical Psychopharmacology, Vol. 26, Núm. 3, pp. 238-249

  2. Improvement in social functioning in outpatients with schizophrenia with prominent negative symptoms treated with olanzapine or risperidone in a 1 year randomized, open-label trial

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 30, Núm. 8, pp. 1515-1522